Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06532240
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-29
Brief Title:
Methylene Blue for the Treatment of Septic Shock
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Initiation of Methylene Blue for Septic Shock in Adults A Randomized Clinical Trial
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of methylene blue among adult patients with septic shock
Detailed Description:
Septic Shock is a leading cause of morbidity and mortality in critically ill patients worldwide
A potential benefit of methylene blue in the treatment of septic shock has recently been described by Estrada In patients with septic shock methylene blue initiated within 24 h reduced time to vasopressor discontinuation and increased vasopressor-free days at 28 days It also reduced length of stay in ICU and hospital without adverse effects
In this randomized controlled trial we aim to evaluate the efficacy and safety of methylene blue on septic shock
A potential benefit of methylene blue in the treatment of septic shock has recently been described by Estrada In patients with septic shock methylene blue initiated within 24 h reduced time to vasopressor discontinuation and increased vasopressor-free days at 28 days It also reduced length of stay in ICU and hospital without adverse effects
In this randomized controlled trial we aim to evaluate the efficacy and safety of methylene blue on septic shock
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None